Compare VNRX & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | PLUR |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 25.5M |
| IPO Year | 2012 | 2001 |
| Metric | VNRX | PLUR |
|---|---|---|
| Price | $1.34 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $1.67 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 237.1K | 27.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,727,384.00 | $1,336,000.00 |
| Revenue This Year | $355.66 | $97.38 |
| Revenue Next Year | $849.08 | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 40.04 | ★ 309.82 |
| 52 Week Low | $0.13 | $1.88 |
| 52 Week High | $3.26 | $5.68 |
| Indicator | VNRX | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 29.18 |
| Support Level | $1.30 | N/A |
| Resistance Level | $1.56 | $2.53 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 59.68 | 0.00 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.